Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions
| Status: | Completed |
|---|---|
| Conditions: | Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - 45 |
| Updated: | 1/25/2018 |
| Start Date: | September 2009 |
| End Date: | September 2009 |
A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions
The objective of this study was to prove the bioequivalence of Roxane Laboratories'
Oxcarbazepine Suspension 600 mg under fasted conditions.
Oxcarbazepine Suspension 600 mg under fasted conditions.
Inclusion Criteria:
- No clinically significant abnormal findings on the physical examination, medical
history, or clinical laboratory results during screening
Exclusion Criteria:
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to oxcarbazepine or any comparable or similar
product.
We found this trial at
1
site
San Antonio, Texas 78217
Click here to add this to my saved trials
